Appointments: Astellas, MorphoSys, AZTherapies, Sigilon Therapeutics, Intec Pharma And Tenaya Therapeutics
Executive Summary
This week's round-up includes promotions at Astellas, new CSOs at MorphoSys and Tenaya, a new president and CMO at AZTherapies, new directors at BioScience Managers, plus board changes at Intec and Sigilon.
You may also be interested in...
Tenaya, With $92m Financing, Aims To Win In Cardiology With Three Platforms
Tenaya is working on three separate approaches (gene therapy, cell therapy and small molecule) to develop new treatments for heart disease.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Pipeline Watch: 16 Approvals And 21 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.